play_arrow
Welcome to Online Radio
The Leading Lifestyle Internet Radio
play_arrow
Music 24/7 - Africana
Online Radio
play_arrow
Music 24/7 - International
Online Radio
play_arrow
Music 24/7 - Gospel
Online Radio
play_arrow
Music 24/7 - Latin America
Online Radio
play_arrow
Talk Shows - Stay Updated
Online Radio
play_arrow
Pillars and Plants - Gospel
Online Radio
play_arrow
Audio Stories - A new movie experience
Online Radio
COVID-19 vaccines need to undergo clinical trial before being administered on Nigerians. The Nigerian Medical Association (NMA) has said.
The president of the association, Innocent Ujah made this known when he featured on Channels TV’s programme, Sunrise Daily.
Ujah said this step needs to be taken to determine the efficacy and adaptability of the vaccines.
He said he is not certain whether Africans were involved in the development of the vaccines, hence the need for evaluation before administration on Nigerians.
“The vaccines will come out, if it comes to Nigeria, we need to quickly do our own evaluation,” he said.
“I’m not sure, I cannot say with 100 percent certain that in the process of developing these vaccines and the clinical trial, whether an African countries are involved.
“If not, then because of the biology, environment, because of the genetics composition, we need to do our own clinical trial, very quickly before it can be used on Nigeria.
“While we do not question the efficacy and safety, the responses vary from place to place. Recall that when we were using chloroquine, the southern part was not responding to chloroquine, some parts of the north were. But in totality it was thought that chloroquine were no longer effective and we changed.”
The NMA president argued that there is need to establish the response of Nigerians because the COVID-19 vaccines were developed under emergency.
Ujah said: “Everything that is happening now is emergency. The vaccines that are being produced within nine months is emergency, otherwise vaccines production does not take within six to nine months.
“It is a process from phase 1, phase 2, phase 4, of course is the marketing, if you can say we can do this with emergency, when it is imported, we should also do our own clinical trial.”
Meanwhile, Kenya has joined the global efforts in search of an effective vaccine for COVID-19, with the start of a trial evaluating the ChAdOx1 nCoV-2019 Oxford coronavirus vaccine.
According to a report on University of Oxford’s website, the trial in Kenya will initially involve 40 frontline workers in Kilifi county.
Once the vaccine safety is confirmed, a further 360 volunteers will be recruited with possible expansion of the trial to Mombasa County.
Recently, FC Barcelona’s forward, Lionel Messi hit a historic landmark when he scored his 644th goal for Barcelona against Real Valladolid in La Liga, making him beat Pelé as the […]
Post comments (0)